Exclusive Summary

• - Off-patent, mature product: Lidocaine 2% gel has been off exclusivity for decades, enabling fast registration and distribution globally.
• - Procedure-driven demand: ~313 million surgeries annually plus tens of millions of catheterizations/endoscopies/intubations create steady, recurring need for mucosal anesthesia/lubrication.
• - Clear standard-of-care: Listed on the WHO Model List; urology and emergency care guidelines commonly recommend intra-procedural lidocaine gel to reduce pain.
• - Competitive but quality-led differentiation: Despite many generics, FDA-GMP and multi-pharmacopoeia API alignment provide audit, tender, and multi-region registration advantages.
• - Cost and supply stability: Typically 50–80% cheaper than brands and can fill shortages with reliable, scalable supply.

Asset Materials

Contact Us for Full Materials